MA33575B1 - Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité - Google Patents

Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité

Info

Publication number
MA33575B1
MA33575B1 MA34676A MA34676A MA33575B1 MA 33575 B1 MA33575 B1 MA 33575B1 MA 34676 A MA34676 A MA 34676A MA 34676 A MA34676 A MA 34676A MA 33575 B1 MA33575 B1 MA 33575B1
Authority
MA
Morocco
Prior art keywords
fxr
linked
activity
compounds
new compounds
Prior art date
Application number
MA34676A
Other languages
Arabic (ar)
English (en)
Inventor
Christoph Steeneck
Olaf Kinzel
Claus Kremoser
Ulrich Abel
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of MA33575B1 publication Critical patent/MA33575B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne des composés qui se lient au récepteur NR1 H4 (FXR) et agissent comme des agonistes dudit récepteur NR1 H4 (FXR). L'invention concerne, en outre, l'utilisation de ces composés dans la préparation d'un médicament destiné à traiter des maladies et/ou autres affections par liaison dudit récepteur nucléaire par lesdits composés, et un procédé de synthèse desdits composés.
MA34676A 2009-08-19 2012-03-08 Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité MA33575B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23511709P 2009-08-19 2009-08-19
EP09010676A EP2289883A1 (fr) 2009-08-19 2009-08-19 Nouveaux composés modulant l'activité du recepteur FXR (NR1H4)
PCT/EP2010/005093 WO2011020615A1 (fr) 2009-08-19 2010-08-19 Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité

Publications (1)

Publication Number Publication Date
MA33575B1 true MA33575B1 (fr) 2012-09-01

Family

ID=41137753

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34676A MA33575B1 (fr) 2009-08-19 2012-03-08 Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité

Country Status (31)

Country Link
US (1) US8952042B2 (fr)
EP (2) EP2289883A1 (fr)
JP (1) JP5692934B2 (fr)
KR (1) KR101712466B1 (fr)
CN (1) CN102548974B (fr)
AU (1) AU2010285175B2 (fr)
BR (1) BR112012003554A2 (fr)
CA (1) CA2771445C (fr)
CL (1) CL2012000369A1 (fr)
DK (1) DK2467366T3 (fr)
EA (1) EA024083B1 (fr)
ES (1) ES2529226T3 (fr)
GE (1) GEP20146109B (fr)
HK (1) HK1172325A1 (fr)
HR (1) HRP20150159T1 (fr)
IL (1) IL217676A (fr)
IN (1) IN2012DN00790A (fr)
MA (1) MA33575B1 (fr)
ME (1) ME02047B (fr)
MX (1) MX2012002119A (fr)
MY (1) MY163109A (fr)
NZ (1) NZ598328A (fr)
PL (1) PL2467366T3 (fr)
PT (1) PT2467366E (fr)
RS (1) RS53812B1 (fr)
SG (1) SG178336A1 (fr)
SI (1) SI2467366T1 (fr)
SM (1) SMT201500029B (fr)
UA (1) UA108209C2 (fr)
WO (1) WO2011020615A1 (fr)
ZA (1) ZA201200730B (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
IL253437A0 (en) * 2011-07-13 2017-09-28 Gilead Sciences Inc New compounds modulate fxr (nr1h4) activity and bind
EP2545964A1 (fr) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
WO2013037482A1 (fr) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
WO2014001278A1 (fr) 2012-06-26 2014-01-03 Aniona Aps Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa
JP6223443B2 (ja) 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
WO2014001279A1 (fr) 2012-06-26 2014-01-03 Aniona Aps Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa
WO2014001280A1 (fr) 2012-06-26 2014-01-03 Aniona Aps Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa
WO2014001281A1 (fr) 2012-06-26 2014-01-03 Aniona Aps Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN102976946A (zh) * 2012-12-13 2013-03-20 烟台泰和新材料股份有限公司 合成间苯二甲酸二甲酯的方法
CN103232378B (zh) * 2013-04-27 2015-11-18 国家海洋局第三海洋研究所 一种含6-溴吲哚满二酮的荔枝螺提取物及制备方法与其抗癌应用
JP6366721B2 (ja) 2013-09-11 2018-08-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物
CA2962572A1 (fr) 2014-09-24 2016-03-31 Gilead Sciences, Inc. Methodes de traitement de maladie du foie a l'aide d'une combinaison d'un inhibiteur de ask1 et d'un agoniste fxr
EP3006939A1 (fr) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Glycoprotéine riche en histidine comme marqueur de l'activation du récepteur farnésoïde X hépatique
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034499A1 (fr) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Nouveaux composés de modulation (FXR NR1H4)
EP3034501A1 (fr) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy contenant des composés de modulation (FXR NR1H4)
DK3253382T3 (da) 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
EP3277286B1 (fr) 2015-03-31 2021-04-21 Enanta Pharmaceuticals, Inc. Dérivés d'acide biliaire utilisés comme agonistes de fxr/tgr5 et leurs procédés d'utilisation
TN2017000426A1 (en) 2015-04-07 2019-04-12 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
WO2017128896A1 (fr) * 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Agoniste de fxr et son procédé de préparation et utilisation associée
CN106995416A (zh) * 2016-01-26 2017-08-01 上海翰森生物医药科技有限公司 Fxr激动剂及其制备方法和应用
CN107021957A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
EA037330B1 (ru) 2016-03-28 2021-03-12 Интерсепт Фармасьютикалз, Инк. Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
WO2017189652A1 (fr) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs procédés d'utilisation
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (fr) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
WO2017201152A1 (fr) * 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs procédés d'utilisation
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201155A1 (fr) * 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
CA2968836A1 (fr) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Composes modulant fxr (nr1h4)
AR108711A1 (es) * 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
MX2018015443A (es) * 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CN106237332A (zh) * 2016-08-11 2016-12-21 河南大学 核受体fxr在肝癌干细胞靶向治疗中的应用
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
JP6915050B2 (ja) * 2016-09-14 2021-08-04 ノバルティス アーゲー Ｆｘｒアゴニストの新規のレジーム
KR20180036522A (ko) * 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CN106588804B (zh) * 2016-12-09 2018-11-09 都创(上海)医药科技有限公司 一种作为类法尼醇x受体(fxr)的化合物的制备方法
WO2018133730A1 (fr) * 2017-01-20 2018-07-26 四川科伦博泰生物医药股份有限公司 Composé hétérocyclique, procédé de préparation et utilisation associés
WO2018153933A1 (fr) 2017-02-21 2018-08-30 Genfit Combinaison d'un agoniste ppar avec un agoniste fxr
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
SI3612520T1 (sl) 2017-04-12 2022-01-31 Il Dong Pharmaceutical Co., Ltd. Izoksazolni derivati kot agonisti nuklearnega receptorja in njihove uporabe
WO2018190643A1 (fr) * 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. Dérivés d'isoxazole en tant qu'agonistes du récepteur nucléaire et leur utilisation
US11339147B2 (en) 2017-05-26 2022-05-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Lactam compound as FXR receptor agonist
KR102400183B1 (ko) 2017-07-06 2022-05-18 수안주 바이오파마슈티컬 컴퍼니 리미티드 Fxr 작용제
CN111655680B (zh) * 2017-09-14 2024-03-05 阿德利克斯股份有限公司 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂
ES2963652T3 (es) 2017-11-01 2024-04-01 Bristol Myers Squibb Co Compuestos espirocíclicos de alquenos como moduladores del receptor x farnesoide
JP7264906B2 (ja) 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
EP3704107B1 (fr) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Composés multicycliques en tant que modulateurs du récepteur de farnésoïde x
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (fr) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole en tant qu'agonistes de fxr et leurs procédés d'utilisation
EP3787669A4 (fr) 2018-04-30 2022-03-30 The Trustees of Indiana University Composés destinés à moduler les niveaux de ddah et d'adma, ainsi que leurs méthodes d'utilisation pour traiter une maladie
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
CN112638473B (zh) 2018-08-08 2022-06-07 因奥必治疗有限公司 用于调节类法尼醇x受体的化合物以及制备和使用所述化合物的方法
BR112021011762A2 (pt) 2019-01-15 2021-11-03 Gilead Sciences Inc Compostos para modulação de fxr (nr1h4)
KR20210123337A (ko) 2019-01-31 2021-10-13 더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드 방향족 고리 또는 헤테로방향족 고리 화합물, 이의 제조 방법 및 이의 의학 용도
AU2020225225B2 (en) 2019-02-19 2022-12-22 Gilead Sciences, Inc. Solid forms of FXR agonists
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US20220226350A1 (en) 2019-05-30 2022-07-21 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
JP2022540699A (ja) 2019-07-18 2022-09-16 ウエヌイグレックオ・ファーマ インターフェロンの有害作用を減少させる方法
JP2023510274A (ja) 2020-01-15 2023-03-13 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｄ型肝炎ウイルスによる感染を処置するためのｆｘｒアゴニストの使用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN113754541A (zh) * 2020-06-02 2021-12-07 深圳湾实验室 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
CA3213217A1 (fr) 2021-04-28 2022-11-03 Raphael Darteil Potentialisation forte d'effets d'agonistes de tlr3 a l'aide d'agonistes de fxr en tant que traitement combine
WO2023090858A1 (fr) * 2021-11-17 2023-05-25 일동제약(주) Procédé de préparation d'un dérivé d'isoxazole, et d'un intermédiaire de celui-ci
WO2023090859A1 (fr) * 2021-11-17 2023-05-25 일동제약(주) Procédé de préparation d'un dérivé d'isoxazole et nouvel intermédiaire associé
TW202408494A (zh) * 2022-06-30 2024-03-01 南韓商日東製藥股份有限公司 異噁唑衍生物及其鹽的新晶型以及包括其之醫藥組合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
EP1285914B1 (fr) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Ligands du récepteur nucéaire nr1h4
AU2003225903A1 (en) 2002-03-21 2003-10-08 Curagen Corporation Methods of using farnesoid x receptor (fxr) agonists
US7319109B2 (en) * 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
US20070166710A1 (en) 2003-03-31 2007-07-19 Markus Stoffel Methods for inhibiting adipogenesis and for treating type 2 diabetes
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
CA2640476A1 (fr) 2006-02-03 2007-08-16 Eli Lilly And Company Composes et procedes pour moduler fxr
CA2651373A1 (fr) 2006-05-24 2007-12-06 Eli Lilly And Company Composes et methodes de modulation de fxr
MX2008014854A (es) 2006-05-24 2008-12-05 Lilly Co Eli Antagonistas de fxr.
EP1894928A1 (fr) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Composes heterocycliques de liaison au fxr
EP1894924A1 (fr) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Composés hétérocycliques de liason du FXR
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
CA2689980A1 (fr) 2007-06-13 2008-12-24 Glaxosmithkline Llc Agonistes de recepteur x de farnesoide
AU2008270784A1 (en) 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid X receptor agonists
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR

Also Published As

Publication number Publication date
PL2467366T3 (pl) 2015-04-30
ZA201200730B (en) 2012-09-26
JP5692934B2 (ja) 2015-04-01
KR20120080574A (ko) 2012-07-17
BR112012003554A2 (pt) 2020-01-28
DK2467366T3 (en) 2015-02-16
MX2012002119A (es) 2012-08-23
SI2467366T1 (sl) 2015-03-31
US20120232116A1 (en) 2012-09-13
RS53812B1 (en) 2015-06-30
SMT201500029B (it) 2015-03-05
NZ598328A (en) 2013-04-26
IN2012DN00790A (fr) 2015-06-26
JP2013502389A (ja) 2013-01-24
ES2529226T3 (es) 2015-02-18
MY163109A (en) 2017-08-15
UA108209C2 (uk) 2015-04-10
WO2011020615A1 (fr) 2011-02-24
CL2012000369A1 (es) 2012-07-13
CA2771445A1 (fr) 2011-02-24
AU2010285175B2 (en) 2014-11-27
EP2289883A1 (fr) 2011-03-02
PT2467366E (pt) 2015-02-06
CN102548974A (zh) 2012-07-04
EP2467366B1 (fr) 2014-11-12
KR101712466B1 (ko) 2017-04-06
EA024083B1 (ru) 2016-08-31
ME02047B (me) 2015-05-20
GEP20146109B (en) 2014-06-10
CA2771445C (fr) 2017-09-12
US8952042B2 (en) 2015-02-10
SG178336A1 (en) 2012-03-29
IL217676A (en) 2015-11-30
HRP20150159T1 (hr) 2015-05-22
EP2467366A1 (fr) 2012-06-27
EA201290047A1 (ru) 2013-09-30
HK1172325A1 (en) 2013-04-19
CN102548974B (zh) 2015-11-25
AU2010285175A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
MA33575B1 (fr) Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
MA41519B1 (fr) Modulateurs du fxr (nr1h4)
MX2009002274A (es) Compuestos de enlace fxr heterociclicos.
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
MX2019011629A (es) Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad.
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA202191566A1 (ru) Соединения, модулирующие fxr (nr1h4)
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA32251B1 (fr) Dihydropyrazolones substituées utilisées comme inhibiteurs de la hif-prolyl-4-hydroxylase
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
NO20092652L (no) Konstruert anti-TSLP-antistoff
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
EA200800100A1 (ru) Соединения азаиндазола и способы применения
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
BRPI1009381B8 (pt) compostos, composição farmacêutica e uso de compostos e de composição farmacêutica
MA34474B1 (fr) Agonistes de gpr40
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
WO2008002571A3 (fr) Inhibiteurs de la protéine humaine tyrosine phosphatase et leurs procédés d'utilisation
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
TW200736189A (en) Indene derivatives, their preparation and use as medicaments